FDA Brief

Warning letters Drugs

FDA warning letter to

Fareva Morton Grove

High riskIssued Mar 3Posted Mar 10Center for Drug Evaluation and Research (CDER)

FDA found microbial contamination risks and data integrity failures at Fareva Morton Grove's OTC drug manufacturing.

What happened

FDA inspected Fareva Morton Grove's drug manufacturing facility at 6901 Golf Road, Morton Grove, Illinois, from August 4 to 12, 2025. FDA found that a manufacturing system used to make OTC drugs was not suitably designed or controlled, had dead-legs (pipe sections where fluid can stagnate) that can harbor microbes, and repeatedly failed a specification; Pseudomonas aeruginosa and Serratia marcescens were found in the system. FDA also found that required microbial identification testing was not done for each batch and that microbiology records were incomplete, including a counted plate with 20 colony-forming units (CFUs) discarded without recording the result.

What FDA found

  1. The company used a manufacturing system that was not suitably designed or controlled, had dead-legs (pipe sections where fluid can stagnate) that can harbor microbes, and repeatedly failed a specification; one qualification study had mostly failing samples, yet it was approved.

    21 CFR 211.63
  2. The company did not perform required identification of all gram-negative rods found in drug product samples since January 2025, despite an increase in colony-forming units.

    21 CFR 211.165(b)
  3. The company did not contemporaneously record negative microbiology plates, automatically entered zero for blank entries, discarded a plate with 20 colony-forming units (CFUs) without recording the count, and could not provide complete microbial sampling results.

    21 CFR 211.194(a)

What FDA wants

FDA tells Fareva to correct the violations promptly and respond in writing within 15 working days with remediation plans, risk assessments, and independent assessments of its laboratory and documentation systems.

Who should pay attention

  • companies whose OTC drugs are made at this site
  • brand owners distributing drugs manufactured by Fareva Morton Grove in the U.S.
  • quality teams responsible for microbial testing and data integrity at contract manufacturers

This is a summary. Read the original letter on fda.gov.

Similar letters to other companies

  1. CNC Noodle Corporation

    FDA warned CNC Noodle Corporation that its Hayward, California noodle plant had insanitary conditions, no pathogen or allergen controls, and mislabeled products.

    High risk
  2. USV Private Limited

    FDA warned USV Private Limited that its sterile injectable manufacturing in Daman, India, had aseptic-processing, facility-design and visible-particulate violations.

    High risk
  3. Next Medical Products Company, LLC

    FDA warns Next Medical Products that its ultrasound gels were contaminated and made without required quality controls or clearance.

    High risk
  4. Northland Nuclear Medicine, LLC

    FDA warned Northland Nuclear Medicine in Bismarck, ND, that its PET drugs are adulterated because it failed to investigate microbial contamination and low yields.

    High risk